Search
Cellectar Biosciences Inc
CLRBAdd to Watchlist
2.570USD
+0.040+1.58%
Close 07-31 16:00（ET）Quotes delayed by 15 min
10.90MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Cellectar Biosciences Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 76.00 and a low of 18.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
10.333
Target Price
+316.67%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Cellectar Biosciences Inc
CLRB
3
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cellectar Biosciences Inc's price target?
Analysts forecast that Cellectar Biosciences Inc's price target is USD 47.00, with the highest forecast at USD 76.00 and the lowest forecast at USD 18.00.
How have Cellectar Biosciences IncCLRB's recent earnings per share performed?
The market expectation was USD -1.33, while Cellectar Biosciences IncCLRB's earnings per share (EPS) for the previous quarter was USD -1.29. EPS for the next quarter is expected at USD -0.48.
What is the analyst rating for Cellectar Biosciences Inc?
Based on the ratings of Cellectar Biosciences Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.